1 result

• Dupixent Cutaneous T-Cell Lymphoma Warning Label Update Being Evaluated by FDA

  September 15, 2025

  Russell Maas

  Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer.